Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders: caution-review of indications and outcome
10.3760/cma.j.issn.1009-9921.2010.10.001
- VernacularTitle:谨慎选择异基因造血干细胞移植治疗骨髓增殖性疾病:适应证探讨及疗效回顾
- Author:
Daihong LIU
- Publication Type:Journal Article
- Keywords:
Myeloproliferative disease;
Hematopoietic stem cell transplantation;
Indication;
Minimal residual disease
- From:
Journal of Leukemia & Lymphoma
2010;19(10):578-579,583
- CountryChina
- Language:Chinese
-
Abstract:
The clinical features were reviewed for polycythemia vera, primary throbocythemia and primary myelofibrosis. Their indications and rational for allogeneic hematopoietic stem sell transplantation (allo-HCT) were recommended. The outcome after allo-HCT was described briefly. The significance of JAK2 mutation, especially V617F, detected for the minimal residual disease was introduced.
